Shots:
Anivive has reported completion of its pivotal trial of Laverdia-CA1 to treat dogs with lymphoma where, the final study site was closed on Dec 12, 2024
The trial assessed Laverdia-CA1 vs PBO in dogs (n=150; selected via AniviveTrial platform from >700 applications) in 12 US sites with results expected in coming months
Additionally,…
